Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis

Geyer, Felipe C.; Lacroix-Triki, Magali; Colombo, Pierre; Patani, Neill; Gauthier, Arnaud; Natrajan, Rachael; Lambros, Maryou; Khalifeh, Ibrahim; Albarracin, Constance T.; Orrù, Sandra; Marchiò, Caterina; Sapino, Anna; Mackay, Alan; Weigelt, Britta; Schmitt, Fernando; Wesseling, Jelle; Sneige, Nour; Reis‐Filho, Jorge S.

doi:10.1111/j.1365-2559.2012.04207.x

Cited by 52 publications

(58 citation statements)

References 53 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basement membrane markers such as collagen IV and laminin cannot be used for distinguishing invasive carcinoma from DCIS or sclerosing lesions as some invasive carcinomas are surrounded by a layer of basement membrane (figure 5). A potential diagnostic pitfall is microglandular adenosis, which has traditionally been regarded as benign, although there is recent evidence that it may be a non-obligate precursor of carcinoma 4. This lesion is composed of tubules or islands of cells that are not in a lobular architecture and lack a myoepithelial layer, although basement membrane is present.…”

Section: Myoepithelial Markersmentioning

confidence: 99%

Use of immunohistochemistry in the diagnosis of problematic breast lesions

Lee

2013

J Clin Pathol

View full text Add to dashboard Cite

Most diagnoses in breast pathology can be made with H&E sections. Nevertheless immunohistochemistry plays a useful supplementary role. This article reviews the common uses of immunohistochemistry in diagnostic breast pathology. It is important to be aware of the limitations of individual antibodies. Such problems can often be overcome by using panels of antibodies. Quality control is also essential: internal and external controls should show appropriate staining. Immunohistochemistry must be interpreted in combination with the morphology seen on H&E sections. Myoepithelial markers, such as smooth muscle actin, smooth muscle myosin heavy chain and p63, are useful for distinguishing invasive carcinoma from sclerosing lesions and ductal carcinoma in situ (DCIS), and in the classification of papillary lesions. Basal cytokeratins can help distinguish epithelial hyperplasia of usual type (UEH) and clonal proliferations such as DCIS and lobular carcinoma in situ (LCIS). UEH usually shows patchy expression whereas DCIS and other clonal proliferations are typically negative. E-cadherin can usually separate DCIS and LCIS: DCIS typically shows membrane staining and most LCIS is negative. Cytokeratins can be used to detect small nodal metastases or subtle invasive carcinomas such as invasive lobular carcinomas. Immunohistochemistry plays a useful role in diagnosing spindle cell lesions such as a panel of cytokeratins to identify spindle cell carcinomas. Immunohistochemistry is helpful in recognising metastases to the breast. Different antibodies are useful for different tumours: WT1 for ovarian carcinoma; TTF1 for pulmonary adenocarcinoma; S100, melan-A and HMB45 for melanoma; and lymphoid markers for lymphoma.

show abstract

Section: Myoepithelial Markersmentioning

confidence: 99%

Use of immunohistochemistry in the diagnosis of problematic breast lesions

Lee

2013

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…The increased frequency of TNBC among AA women therefore contributes to disparities in breast cancer outcome that are well-documented in the United States, with higher mortality rates among AA compared to WA women. TNBC is thought to arise from different pathogenetic pathways compared to non-TNBC, and it is associated with different reproductive history risk factors 5-7 . Histopathologic patterns of benign breast conditions (commonly referred to as benign breast disease [BBD]), such as hyperplasia, atypia, and lobular carcinoma in situ (LCIS) are associated with an increased risk for future breast cancers that are more likely to be of the ER-positive/non-TNBC phenotype.…”

Section: Introductionmentioning

confidence: 99%

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer

et al. 2017

View full text Add to dashboard Cite

Importance African American (AA) women have a two-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor and HER2/neu (triple negative breast cancer, TNBC) compared with White/Caucasian Americans (WA). TNBC likely arises from different pathogenetic pathways compared to non-TNBC, and benign breast disease (BBD) predicts for future non-TNBC. Objective To determine whether AA identity remained associated with TNBC among women with a prior diagnosis of BBD. Design Retrospective analysis; January 1, 1994-December 31, 2005; mean follow-up 10.2 years. Setting Henry Ford Health System in metropolitan Detroit, Michigan; an integrated multihospital, multispecialty health care system. Participants 2,588 AA and 3,566 WA patients age 40-70 years with biopsy-proven BBD diagnosed 1/1/1994 to 12/31/2005. Main Outcome Measures Subsequent breast cancer, stratified by phenotype. Results BBD detection and management were similar for the AA and WA patients. Subsequent breast cancers developed in approximately 4% of AA patients (mean 6.8 years following BBD diagnosis) and WA patients (mean 6.1 years). More than three-quarters of subsequent cancers in each subset were DCIS or Stage I. The 10-year probability estimate for developing TNBC was 0.56% (95% confidence interval 0.32-1.0) for AA versus 0.25% for WA (95% confidence interval 0.12-0.53). Among the 73 AA patients that developed subsequent invasive breast cancer, 24.2% were TNBC compared to 7.4% of the 111 subsequent invasive BC cases (p=0.0125) among the WA patients. Conclusion and Relevance AA identity persisted as a significant risk factor for TNBC in our study, the largest analysis to date of BBD and subsequent breast cancer phenotypes in a diverse patient population managed equitably. This suggests that AA identity is associated with inherent susceptibility for TNBC pathogenetic pathways.

show abstract

“…The role of microglandular adenosis as a potential precursor of invasive breast cancer has long been a matter of controversy. Molecular analysis [16][17][18][19] has demonstrated that at least a subset of MGA shows recurrent losses of chromosome 5q and gains of 8q. The pattern of genetic aberrations found in MGA differs from that of other non-obligate precursors of ER-positive breast cancer, and is reminiscent of those reported specifically for high-grade triple-negative breast carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology

Zhong

et al. 2014

Pathology

View full text Add to dashboard Cite

Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis

Abstract: Our results support the contention that MGA can be a clonal lesion and non-obligate precursor of triple-negative breast cancer.

Cited by 52 publications

References 53 publications

Use of immunohistochemistry in the diagnosis of problematic breast lesions

Use of immunohistochemistry in the diagnosis of problematic breast lesions

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer

Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology

Contact Info

Product

Resources

About